Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

NCT06731946 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-12-13

No results posted yet for this study

Summary

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

Conditions

  • Intracranial Arterial Aneurysm

Interventions

DEVICE

Flow diverting

Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.

Sponsors & Collaborators

  • Yibin Fang

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-29
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06731946 on ClinicalTrials.gov